Last reviewed · How we verify
urea-based cream
At a glance
| Generic name | urea-based cream |
|---|---|
| Also known as | Nexavar is the brand name of sorafenib |
| Sponsor | Chinese Anti-Cancer Association |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PHASE3)
- Efficacy and Safety of Moisturising Cream With or Without Vitamin E and Urea Cream in Palmar-plantar Erythrodysesthesia (NA)
- Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy (NA)
- Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR (NA)
- Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC (PHASE1)
- Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases (PHASE1)
- Effectiveness of an N-acetylcysteine and Urea-based Cream in Prevention of Capecitabine-induced HAND-foot Syndrome in Breast Cancer Patients (NA)
- Topical Cosmetic Products for Hand and Foot Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- urea-based cream CI brief — competitive landscape report
- urea-based cream updates RSS · CI watch RSS
- Chinese Anti-Cancer Association portfolio CI